 Atea Pharmaceuticals Inc NASDAQ: AVIR has reported data from the Phase 2 MOONSONG trial of AT-527 in the outpatient setting in patients with mild or moderate COVID-19. Related: Atea Unveils Trial Amendments, New Data For COVID-19 Program. 